1-(6-Methylimidazo[1,2-a]pyridin-2-yl)ethan-1-one | 1538994-41-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 1-(6-Methylimidazo[1,2-a]pyridin-2-yl)ethan-1-one
• 英文别名: 1-(6-methylimidazo[1,2-a]pyridin-2-yl)ethanone
• CAS: 1538994-41-0
• 化学式: C₁₀H₁₀N₂O
• mdl: MFCD23904669
• 分子量: 174.2
• InChiKey: RPDNDVDPLAOFFG-UHFFFAOYSA-N

物化性质

• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  34.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：PTC Therapeutics, Inc.

  公开号：US20180105526A1

  公开（公告）日：2018-04-19

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组成物和使用方法。
• Duocarmycin ADCs showing improved in vivo antitumor activity
  申请人：Byondis B.V.

  公开号：US11382982B2

  公开（公告）日：2022-07-12

  The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

  本发明涉及含杜卡霉素的抗体药物偶联物(ADCs)，用于治疗表达HER2的实体瘤和血液系统恶性肿瘤，尤其是乳腺癌、胃癌、膀胱癌、卵巢癌、肺癌、前列腺癌、胰腺癌、结直肠癌、头颈部鳞状细胞癌或骨肉瘤，以及急性淋巴细胞白血病。特别地，本发明涉及用于治疗HER2免疫组化(IHC)2+或1+且HER2荧光原位杂交(FISH)阴性肿瘤状态的人类实体瘤的含杜卡霉素的ADCs。更有利的是，本发明涉及用于治疗三阴性乳腺癌(TNBC)的含杜卡霉素的ADCs。
• DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY
  申请人：Synthon Biopharmaceuticals B.V.

  公开号：US20190314513A1

  公开（公告）日：2019-10-17

  The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
• HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
  申请人：JUBILANT EPISCRIBE LLC

  公开号：US20210371431A1

  公开（公告）日：2021-12-02

  The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.
• US9586955B2
  申请人：——

  公开号：US9586955B2

  公开（公告）日：2017-03-07